HGF and hepatocellular carcinoma: For patients resistant to immune checkpoint inhibitor treatment, cabozantinib, exerted its immune regulation effects via releasing HGF (hepatocyte growth factor) correlated DCs suppression and Tregs promotion, is currently being explored in a phase III clinical trial to verify its therapeutic capacity for HCC (NCT04588051).